Results 21 to 30 of about 30,994 (308)

Manufacture of Tl targets by electrodeposition for the study of excitation functions of 203Pb [PDF]

open access: yesEPJ Web of Conferences, 2023
Natural Tl targets were manufactured by electrochemical deposition on a foil gold backing. The electrochemical parameters were defined after several experiments and reverse pulse potential was chosen to avoid the formation of filaments and dendrites ...
Sounalet Thomas   +10 more
doaj   +1 more source

Metabolic, hormonal and performance effects of isomaltulose ingestion before prolonged aerobic exercise: a double-blind, randomised, cross-over trial

open access: yesJournal of the International Society of Sports Nutrition, 2021
Background Isomaltulose has been discussed as a low glycaemic carbohydrate but evidence concerning performance benefits and physiological responses has produced varying results.
Hannah L. Notbohm   +8 more
doaj   +1 more source

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

open access: yesCell Metabolism, 2021
Summary Uncertainty exists as to whether the glucose-dependent insulinotropic polypeptide receptor (GIPR) should be activated or inhibited for the treatment of obesity. Gipr was recently demonstrated in hypothalamic feeding centers, but the physiological
Qian Zhang   +35 more
semanticscholar   +1 more source

GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function.

open access: yesCell Reports, 2023
Glucagon-like peptide 1 (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIPR) receptors are G-protein-coupled receptors involved in glucose homeostasis. Diabetogenic conditions decrease β-arrestin 2 (ARRB2) levels in human islets.
Nour Zaïmia   +8 more
semanticscholar   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

open access: yesJCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
F. Willard   +17 more
semanticscholar   +1 more source

GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.

open access: yesEuropean Journal of Endocrinology, 2023
OBJECTIVE Drugs targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) are emerging as treatments for type-2 diabetes and obesity.
Morten S. Hansen   +15 more
semanticscholar   +1 more source

Glucose metabolism and incretins level in morbidly obese patients and in patients after biliopancreatic diversion performed for morbid obesity

open access: yesОжирение и метаболизм, 2014
We’ve studied a carbohydrate metabolism in morbidly obese (MO) patients and the patients after bariatric surgery. The patients of the 1st group had BMI>40 (n=22) and no history of diabetes mellitus.

doaj   +1 more source

Potential of using polyethylene as viscosity enhancer of palm oil to use as a lubricating oil

open access: yesAdvances in Mechanical Engineering, 2020
Biodegradable vegetable oil-based lubricating oil is a better auxiliary for mineral-based lubricants as their viscosity index, flash point, lubricity is high.
TKKS Pathmasiri, GIP Perera
doaj   +1 more source

Imaging modalities to assess oxygen status in glioblastoma

open access: yesFrontiers in Medicine, 2015
Hypoxia, the result of an inadequacy between a disorganized and functionally impaired vasculature and the metabolic demand of tumor cells is a feature of glioblastoma.
Aurélien eCorroyer-Dulmont   +35 more
doaj   +1 more source

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

open access: yesTrends in endocrinology and metabolism, 2020
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM). However, dose-related gastrointestinal effects limit efficacy, and therefore
R. Samms, M. Coghlan, K. Sloop
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy